On-Demand CME Videos
FC24: Gamechangers in Nonsteroidal Topical Management of Atopic Dermatitis: The Next Generation: An Online Activity
About
FC24: Gamechangers in Nonsteroidal Topical Management of Atopic Dermatitis: The Next Generation: An Online Activity
This activity is supported by an educational grant from Dermavant Sciences, Inc.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 21, 2024
December 21, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Review emerging long-term data for nonsteroidal topical agents for the treatment of atopic dermatitis (AD)
Identify patients with AD who are eligible candidates for nonsteroidal topical agents
Intended Audience
Faculty
Shawn Kwatra, MD
Joseph W. Burnett Professor and Chairman
Department of Dermatology
University of Maryland School of Medicine
Baltimore, MD
G. Michael Lewitt, MD
Illinois Dermatology Institute - Partner
DeNova Research - Director of Medical Dermatology Research
Associate Professor Dermatology Rosalind
Franklin - Chicago Medical School
Chicago, IL
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board: Abbvie, Amgen, Arcutis, Aslan Pharmaceuticals, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Incyte Corporation, Johnson & Johnson, Novartis, Leo, Regeneron, Sanofi Grant/Research Support: Galderma, Incyte, Pfizer, and Sanofi
Consultant: Abbvie, Amgen, Arcutis, Aslan Pharmaceuticals, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Incyte Corporation, Johnson & Johnson, Novartis, Leo, Regeneron, Sanofi
Advisory Board: Dermavant, Pfizer, Galderma, Janssen, Lilly, UCB Grant/Research Support: Amgen, Abbvie, Lilly, DermTech, Dermavant, Aobiome, Novan
Consultant: Dermavant, Pfizer, Galderma, Janssen, Lilly, UCB Speakers’ Bureau or Honoraria: Abbvie, Arcutis, Lilly, Janssen, Pfizer, Dermavant, BMS, Incyte, UCB, Orthodermatologics
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.